Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors:
- Jena D. FrenchJFJena D. French
- Bryan R. HaugenBHBryan R. Haugen
- Francis P. WordenFWFrancis P. Worden
- Daniel W. BowlesDBDaniel W. Bowles
- Andrew G. GianoukakisAGAndrew G. Gianoukakis
- Bhavana KondaBKBhavana Konda
- Ramona DaduRDRamona Dadu
- Eric J. ShermanESEric J. Sherman
- Shaylene McCueSMShaylene McCue
- Nathan R. FosterNFNathan R. Foster
- Yuri E. NikiforovYNYuri E. Nikiforov
- Ticiana D.J. FariasTFTiciana D.J. Farias
- 26 June 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (17) , 3757-3767
Abstract
Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients. Patients and Methods: We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days. Results: In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1. Conclusions: Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.Keywords
All Related Versions
Funding Information
- International Thyroid Oncology Group
- Merck Company Foundation
- Cancer League of Colorado (193539-PN)
This publication has 39 references indexed in Scilit:
- Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s ChoiceEuropean Journal of Cancer, 2023
- First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness AnalysisClinical Genitourinary Cancer, 2022
- Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trialCancer, 2022
- Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trialCancer, 2022
- Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United StatesAdvances in Therapy, 2020
- PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid CarcinomaEndocrine Pathology, 2018
- Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodulesCancer, 2018
- Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013JAMA, 2017
- Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput SequencingThe American Journal of Human Genetics, 2016
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsCancer Letters, 2013